NC-KBI-BIOPHARMA
23.7.2024 14:01:30 CEST | Business Wire | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced that it has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed contract extends through 2029 with a notable amendment that outlines a purchase commitment for two therapeutic products representing an incremental value of approximately $250 million through the end of the renewed term.
In addition, KBI, in late June, completed a successful regulatory inspection by the U.S. Food and Drug Administration (FDA) of its mammalian operation in Durham, North Carolina. This regulatory inspection enables the company’s North Carolina operations to begin providing a mammalian drug substance commercially to one of its key strategic customers. It also demonstrates KBI’s ability to act as a preferred partner for large volume commercial therapeutic manufacturing.
“As KBI continues fulfilling its commitment to our customers in helping solve their complex manufacturing challenges, this commercial contract extension allows us to demonstrate our approach as a next-generation CDMO,” said J.D. Mowery, President and CEO of KBI Biopharma. “With this agreement as well as our successful FDA regulatory inspection, we’re driving breakthroughs in biopharmaceutical development and manufacturing that help bring new therapies to market.”
He concluded, “By establishing these trusted, long-term partnerships with global pharmaceutical leaders, we’re able to positively impact the lives of patients worldwide.”
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. With each of its 500+ customer partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global customers with six locations in Europe and the USA. More information is available at www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723243720/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIPPON KINZOKU Accelerates Global Sales of Ultra-Thin Electrical Steel Strips "GT Series" and "ST Series" as "Fine Eco Metal" Environmentally Friendly Products9.7.2026 10:01:00 CEST | Press release
- Delivering the ultimate balance of “Ultra-Thinness” and “Low Core Loss” to drastically reduce high-frequency energy loss - NIPPON KINZOKU CO., LTD. (Headquarters: Minato-ku, Tokyo; President: Yasushi Shimokawa; TOKYO: 5491) and its subsidiary, NIKKIN DENJI KOGYO CO., LTD. (Headquarters: Kawaguchi, Saitama; President: Akira Nishimura), are launching a strategic sales initiative for their ultra-thin Grain-Oriented (GT Series) and Non-Oriented (ST Series) electrical steel strips under the brand name "Fine Eco Metal". This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709899733/en/ By reducing the thickness of the electrical steel strip, eddy current loss (core loss) can be significantly lowered. Eddy currents are electrical currents generated within the electrical steel strip by alternating magnetic fields; they are a primary factor that increases core loss. "Fine Eco Metal" is a brand name for our proprietary "Eco-Product" se
3E Acquires Yordas Group: Expanding Leadership in Product Compliance by Augmenting 3E’s Global Regulatory Content and Expertise, and Adding REACH Registration Services9.7.2026 10:00:00 CEST | Press release
3E, the leading global provider of expert-led AI compliance solutions for chemical and workplace safety, product stewardship, and sustainable supply chains, today announced its acquisition of Yordas Group, a leading international provider of scientific consulting and regulatory content services across chemical management, product stewardship, sustainability, and regulatory compliance. Headquartered in Lancaster, UK, with operations in Germany, Canada, Türkiye, and Japan, Yordas serves global brands through its Scientific Services, Regulatory Intelligence, Product Compliance, and Hazard Communication offerings. Solidifying 3E’s Global Regulatory Content Leadership and Breadth of Expertise The acquisition extends 3E's regulatory content leadership and joins two organizations that pride themselves on building and aligning the industry’s top talent of advanced regulatory and chemical experts. It further solidifies 3E as the product compliance solution provider with the industry's broadest
ROYC and PwC Sweden Collaborate to Digitalize Private Equity Structuring & Fund Operations9.7.2026 10:00:00 CEST | Press release
ROYC today announces a strategic collaboration with PwC Sweden to accelerate the digitalization of the GP value chain. The partnership brings together PwC Sweden's market-leading expertise in fund formation and structuring with ROYC’s platform capabilities, with the shared aim of compressing time-to-market, eliminating manual friction in early-phase workflows, and improving the client experience across the full fund lifecycle for fund managers operating across any jurisdiction. "Digitalization of fund operations is overdue. We work alongside fund managers on structuring decisions, regulatory requirements, and operational complexity every day, and the inefficiencies in the early phase are real and costly. What excites me about this collaboration is the practical ambition behind it: taking the knowledge we apply manually today and making it available through a platform that GPs can use from day one. Working directly with the ROYC team in Stockholm makes iteration fast, and the applicatio
Hytera Introduces PDC580 Dual-Mode Rugged Radio to Support Seamless Communication Across Critical Operations9.7.2026 09:25:00 CEST | Press release
Hytera, a leading global provider of critical communications technologies and solutions, announced the launch of the PDC580 Dual-Mode Rugged Radio, developed for organizations that continue to rely on PMR while expanding broadband communications across increasingly distributed operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708879078/en/ Built to connect LTE and PMR, the Hytera PDC580 brings dual-mode communication into one compact rugged radio. “The transition from narrowband to broadband is not an overnight replacement,” said Arthur Luo, Product Manager of Hytera Smart Terminal BU. “Many organizations will operate mixed communication environments for years to come. The PDC580 is designed to make that transition seamless, allowing teams to stay connected without changing established operational workflows.” Many frontline operations involve personnel working across different locations, departments, and network
LR Invests Over €2 Million in Quality and Growth9.7.2026 09:00:00 CEST | Press release
Global demand for innovative health products continues to grow, and with it the requirements for quality, supply reliability and production capacity. LR Health & Beauty is therefore strengthening its Ahlen headquarters with an investment of more than €2 million, laying the foundation for further growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709000261/en/ New, state-of-the-art production line in Ahlen, Germany, manufacturing LR 5in1 Beauty Elixir and LR 5in1 Men's Shot. At the heart of the investment is a new, state-of-the-art production line. LR will use it to fully consolidate the manufacturing of its successful 5-in-1 products at its Ahlen headquarters. This includes, among others, the LR 5in1 Beauty Elixir and the LR 5in1 Men’s Shot. At the same time, the new facility creates the conditions for future product innovations in modern nutritional supplement concepts. By bringing the complete production of its 5-in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom